A panel of glycan cell surface markers define pluripotency state and promote safer cell-based therapies.
In a recent study in Nature Biotechnology, Tang et al. (2011) describe a new marker of pluripotency, stage-specific embryonic antigen-5 (SSEA-5), and show that this oligosaccharide, together with two other surface antigens, can be used to remove all tumor-initiating cells from prospective cell transplants.